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Summary
The TSC1-TSC2 complex has recently been implicated in cell survival responses. We observed that NF-kB signaling is atten-
uated in TSC1- and TSC2-deficient MEFs concomitant with reduced survival following DNA damage or TNFa stimulation.
Reconstitution of TSC2 expression in TSC22/2MEFs rescued survival in an NF-kB activity-dependent manner. Furthermore,
in TSC22/2MEFs, the rapamycin-mediated inhibition of deregulated mTOR activity restored NF-kB activation and survival.
This rapamycin-mediated effect was reversed by inhibition of NF-kB transcriptional activation or by inhibition of ERK1/2
MAPkinase or PI-3Kpathways, which lie on signaling cascades that lead toNF-kBactivation. These results provide evidence
for a crosstalk between the TSC/Rheb/mTOR pathway and the NF-kB induction pathways and indicate that NF-kB functions
as an important survival factor that regulates TSC2-dependent cell survival.Introduction
Autosomal dominant mutations in the tumor suppressor genes
TSC1 (Hamartin) or TSC2 (Tuberin), give rise to hamartomatous
lesions or tubers. The common hamartomas are subependymal
giant cell astrocytomas (SEGAs) in the brain, rhabdomyomas of
the heart, and angiomyolipomas of the kidneys (Kwiatkowski
and Manning, 2005). Genetic studies and molecular character-
ization have placed the TSC1/2 complex in the phosphatidylino-
sitol 3-OH kinase (PI-3K)-mammalian target of rapamycin
(mTOR)/S6K1/4E-BP1 signaling pathway, directly downstream
of Akt and upstream of mTOR. The C terminus of TSC2 harbors
a GTPase-activating protein (GAP) domain that inhibits mTOR
by stimulating the GTP hydrolysis activity of a member of the
Ras superfamily GTPases, Ras homology enriched in brain
(Rheb) (Kwiatkowski andManning, 2005). Therefore, RhebGTP
level and mTOR activity are upregulated in TSC1- and TSC2-
deficient cells. Recent studies have shown that lack of TSC1
or TSC2 leads to downregulation of Akt and apoptosis under
conditions of serum starvation or during exposure to chemo-
therapeutic agents (Harrington et al., 2004; Shah et al., 2004).
The increased sensitivity of TSC22/2 mouse embryonicCANCER CELL 10, 215–226, SEPTEMBER 2006 ª2006 ELSEVIER INC. DOfibroblasts (MEFs) to DNA-damaging reagents has been as-
cribed to insulin/IGF-1 resistance, as rapamycin treatment re-
stores insulin-stimulated Akt activation and this process corre-
lates with increased chemoresistance in these cells. Since
a better understanding of rapamycin-induced chemoresistance
mechanisms would be important for identifying targets for ther-
apeutic intervention, we investigated if additional signaling path-
ways are involved in the TSC1-TSC2 complex-dependent cell
survival response.
The nuclear factor-kappa B (NF-kB) transcription factors are
important antiapoptotic factors that regulate cell survival (Ghosh
and Karin, 2002; Wang et al., 2002). The mammalian NF-kB/Rel
family consists of five members (p65/RelA; RelB; c-Rel; p105,
which is processed into p50; and p100, which is processed
into p52) that bind to cognate DNA sequence as homodimers
or heterodimers andelicit transcription of a number of genes.Un-
der basal conditions, the p50/p65 NF-kB complex is seques-
tered by IkB family proteins. In response to specific stimuli, IkB
proteins in complex with NF-kB are phosphorylated at Ser32
and Ser36 by the upstream protein kinase complex containing
the IkB kinases a and b (IKK-a/1, IKK-b/2), the scaffold protein
NF-kB essential modulator (NEMO)/IKKg, and ELKS (DucutS I G N I F I C A N C E
The triene macrolide rapamycin has been identified as a therapeutic reagent for a wide variety of cancers with defects in the PI-3K-
TSC1/2-mTOR signaling pathway. However, acquisition of resistance to chemotherapy remains a major problem in cancer therapy.
Since rapamycin-mediated increases in apoptosis resistance in TSC2-deficient cells can be reversed by inhibition of NF-kB activation
or its upstream signaling pathways, our studies suggest the potential use of NF-kB signaling inhibitors as adjuvants to maximize the
efficacy of rapamycin-based therapeutics for TSC-derived tumors.I 10.1016/j.ccr.2006.08.007 215
A R T I C L ESigala et al., 2004). TheN-terminally phosphorylated IkBproteins
are recognized by SCF-bTrCP, rapidly polyubiquitylated, and
subsequently degraded by the 26S proteasome (Ben-Neriah,
2002). The removal of IkB allows the p50/p65 NF-kB complex
to bind specific DNA sequences and regulate the expression of
its target genes. Recent studies indicate that posttranslational
modification of NF-kB is critical for its transcriptional compe-
tence (Campbell and Perkins, 2004; Ghosh and Karin, 2002).
A number of signaling events, including phosphorylation and/
or ubiquitylation, are important for NF-kBactivation (Chen, 2005;
Hayden and Ghosh, 2004; Viatour et al., 2005). Activation of NF-
kB by the inflammatory cytokine tumor necrosis factor a (TNFa)
requires activation of PI-3K and its downstream target, Akt. Akt
mediates IKKa phosphorylation at Thr23 (Ozes et al., 1999).
NF-kB activation following DNA damage by doxorubicin (adria-
mycin) and camptothecin also involves a sequential activation
of kinase cascades, although the molecular mechanism is inde-
pendent from cytokine signaling and less well understood.
NF-kB is activated by a RIP- and IKK-dependent mechanism
following DNA damage, but the functional role of RIP in this re-
sponse pathway is distinct from the TNFR signaling pathway
(Hur et al., 2003). Huang et al. reported that, following DNA dam-
age, ATM phosphorylates NEMO, leading to replacement of in-
hibitory SUMOwith ubiquitin on NEMO. This substitution allows
nuclear exit and association with IKK, resulting in IKK activation
(Huang et al., 2003). Additionally, UV radiation or doxorubicin-
induced DNA damage can induce IKK-independent IkBa degra-
dation (Kato et al., 2003; Tergaonkar et al., 2003). It is well known
that ERK1/2 is involved in cell survival signaling (Gardner and
Johnson, 1996; Tran et al., 2001; Xia et al., 1995). ERK is acti-
vated in response to cisplatin in ovarian cancer cells and may
function in the response to DNA damage (Persons et al., 2000;
Tang et al., 2002), although its role in mediating apoptosis re-
mains to be clarified (MacKeigan et al., 2000; Wang et al.,
2000). However, in this regard, tumors with constitutive ERK
activation undergo apoptosis when ERK activity is blocked
(Hoshino et al., 2001). ERK1/2 may also serve as an activator
of NF-kB responses by stimulating p90Rsk activation (Ghoda
et al., 1997; Panta et al., 2004; Ryan et al., 2000; Schouten
et al., 1997). Doxorubicin-induced DNA damage has also been
shown to activate an ATM-dependent, but p53-independent,
MEK/ERK/p90Rsk/IKKsignalingpathwaythat leads toNF-kBac-
tivation and cell survival (Panta et al., 2004). Also, MEKK1 and
MEKK3 regulate IKKa and IKKb activation, and a dominant-neg-
ative MEKK1 blocks Raf-1-induced NF-kB activation (Baumann
et al., 2000; Lee et al., 1998; Yang et al., 2001). NF-kBDNA bind-
ing is also abolished by theMEK1 inhibitor PD98059 (Ryan et al.,
2000). In this report, we show that one of the key mechanisms of
cell survival mediated by the TSC1-TSC2 complex involves the
activation of NF-kB. The TSC1-TSC2 complex modulates NF-
kB activity by regulating Akt and ERK1/2 signaling cascades
that lead toNF-kBactivation. These findingsmay have therapeu-
tic implications for the treatment of TSC-derived tumors.
Results and discussion
TSC1- and TSC2-deficient cells are more sensitive
to DNA damage and TNFa-induced cell death
and show reduced NF-kB activation
The TSC1-TSC2 complex has recently been implicated in the
cell survival response. To investigate TSC1-TSC2 complex-216mediated prosurvival signaling, we treated TSC12/2 or TSC22/2
MEFs with reagents known to induce cell death, and by exten-
sion, cell survival responses. Compared to MEFs obtained
from TSC2+/+ p532/2 and TSC1+/+ p53+/+ littermates, TSC22/2
p532/2 MEFs or TSC12/2 p53+/+ MEFs showed increased sus-
ceptibility to cell death following treatment with the alkylating
agent methyl methanesulfonate (MMS) (0.01% volume/volume)
or TNFa (10 ng/ml) plus cycloheximide (5 mg/ml) (Figures 1A and
1B). Cycloheximide alone had no effect (data not shown). Sin-
gle-blind quantitation of cell viability showed that, in the pres-
ence of either MMS or the anthracycline chemotherapeutic
compound doxorubicin, there was approximately a 5-fold in-
crease (p < 0.001) in cell death in MEFs deficient for TSC2
(55.12% 6 1.84% for doxorubicin and 56.15% 6 4.24% for
MMS) in comparison to TSC2+/+ p532/2 (henceforth referred
to as wild-type) MEFs (14.16% 6 5.26% and 12.88% 6
4.94%, respectively). TNFa plus cycloheximide treatment also
resulted in a similar increase in cell death after 3 hr (70.87% 6
9.11%; Figure 1C). Immunofluorescence staining using phos-
pho-ATM Ser1981 and g-(phospho)H2AX antibodies confirmed
that ATM was activated in response to MMS treatment in both
wild-type and TSC22/2 MEFs (Figure 1D). Thus, the DNA dam-
age response checkpoint is functional in the absence of TSC2.
However, consistent with increased cell death, caspase 3 acti-
vation was significantly higher in TSC22/2MEFs following expo-
sure toMMSand TNFa (Figures S1A and S1B in the Supplemen-
tal Data available with this article online). In summary,
a deficiency in either of the TSC genes, TSC1 or TSC2, both of
which are essential for a functional TSC1/2 complex, results in
increased cell death following exposure to DNA-damaging re-
agents or to TNFa. It is interesting to note that the attenuation
of prosurvival responseswas observed in TSC22/2MEFs, which
are p53 deficient, as well as in the TSC12/2 MEFs, which ex-
press wild-type p53, indicating that the increased apoptosis ob-
served in cells lacking functional TSC1/2 complex occurs inde-
pendently of p53 function.
NF-kB activation is common to and involved in the protection
against both TNFa- and DNA damage-induced cell death. Since
TSC22/2MEFs were sensitive to both these apoptosis-inducing
stimuli, we tested the status of NF-kB signaling in these cells. In
response toMMSordoxorubicin, or alternatively to inflammatory
cytokines, such as TNFa, interleukin 1 (IL-1), and the bacterial li-
popolysaccharide (LPS), the specific DNA binding activity of
p65:p50 NF-kB complexes in nuclear extracts from wild-type
MEFs increased, asdeterminedbyNF-kBelectrophoreticmobil-
ity shift assay (EMSA). In contrast, no quantitative increase in ac-
tive NF-kB-DNA complexes was observed in the TSC22/2MEFs
following these treatments. Control binding of Oct-1 to a specific
probe showed no difference in electromobility shift upon induc-
tion in either cell line (Figure 1E). Additionally, total p65 and IkBa
protein levels, when normalized to actin, were similar between
the wild-type and TSC22/2MEFs (Figure S1C). Taken together,
these results indicate that TSC22/2MEFs are more susceptible
to cell death, and decreased cell survival correlateswith a defect
in NF-kB activation. Therefore, NF-kB activation may play a role
in TSC1-TSC2 complex-dependent prosurvival signaling.
TSC22/2 MEFs show reduced induction
of NF-kB-dependent transcripts
NF-kB activation culminates in the transcription of NF-kB target
genes. To verify if NF-kB-regulated gene expression isCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 1. Increased DNA damage sensitivity and reduced NF-kB activation in TSC1- and TSC2-deficient cells
A and B: TSC2+/+ p532/2 (WT), TSC22/2 p532/2 littermate-derived MEFs (A), or TSC1+/+ p53+/+ and TSC12/2 p53+/+ littermate-derived MEFs (B) were treated with
0.01% MMS or 10 ng/ml TNFa plus cycloheximide (CHX) (5 mg/ml) for 4 hr or left untreated. Viable cells were fixed and stained with crystal violet.
C:WTand TSC22/2MEFs were treated with 0.01% MMS for 2 hr, 0.7 mg/ml doxorubicin (Dox) for 6 hr, and 10 ng/ml TNFaplus cycloheximide for 3 hr or treated with
cycloheximide alone or DMSO vehicle alone. Percentage of cell death is represented in the bar graph. Bars in graphs represent means6 standard deviations.
D: Active ATM and gH2AX foci in wild-type and TSC22/2 MEFs were detected by immunofluorescence after MMS treatment for 2 hr.
E: Wild-type and TSC22/2MEFs were either untreated (lanes 1, 4, 7, 11, and 15) or treated with 0.7 mg/ml doxorubicin for 2 hr (lanes 3 and 6), 0.01% MMS for 2 hr
(lanes 2 and 5), 10 ng/ml TNFa for 20 min (lanes 8, 12, and 16), 10 ng/ml IL-1 for 30 min (lanes 9, 13, and 17) or 10 ng/ml LPS for 30 min (lanes 10, 14, and 18), and
NF-kB (top panel) and Oct-1 (bottom panel) DNA binding activity was detected by EMSA assays from wild-type, TSC12/2, or TSC22/2 MEFs as indicated.
F: Real-time PCR analyses of indicated genes from wild-type and TSC22/2 MEFs following treatment with MMS for 2 hr or doxorubicin for 6 hr.compromised in the absence of TSC2, we quantitatively ana-
lyzed the expression profile of a number of NF-kB-inducible
mRNAs by real-time PCR analyses, following exposure of
TSC22/2 or wild-type MEFs to MMS or doxorubicin. Cox2,
IkBa, and IL-1a mRNAs were induced approximately 2- to 2.5-
fold after 2 hr of MMS treatment (Figure 1F). Cox2 and IkBa re-
sponded similarly to treatment with doxorubicin, showing a 1.5-
to 2.5-fold increase in abundance. On the other hand, none of
these genes showed any induction following MMS or doxorubi-
cin treatment in TSC22/2 MEFs. Similar results were obtained
with other NF-kB target genes, such as iNOS and IL-6, but not
with other genes not regulated by NF-kB (data not shown). How-
ever, the identities of NF-kB target genes that directly mediate
the antiapoptosis response remain unclear. We did not observe
inducible differences in antiapoptotic genes, such as IAP1 or
Bcl-xL, following MMS stimulation of TSC2+/+ in our real-time
PCR analyses under the conditions that we have used. Nonethe-
less, consistent with decreased DNA binding of NF-kB com-
plexes, the transcriptional upregulation of some NF-kB-CANCER CELL SEPTEMBER 2006dependent genes was compromised in TSC2-deficient MEFs,
following exposure to DNA-damaging reagents.
TSC2 knockdown or Rheb expression in human tumor-
derived cell lines results in decreased NF-kB activation,
while reconstitution of TSC2 in TSC22/2 MEFs restores
NF-kB activation and NF-kB-dependent resistance
to DNA damage-induced cell death
Given the possibility that TSC22/2MEFsmight have compensa-
tory mutations in other pathways that result in the attenuation of
NF-kB activation, we investigated whether acute disruption of
TSC2 signaling in other genetic backgrounds has a similar effect
on NF-kB activation. Toward this goal, we tested if siRNA-medi-
ated knockdown of TSC2 can recapitulate the attenuation of
NF-kB activation in HEK293 cells (Figure 2A). Compared to con-
trol siRNA-treated cells, there was a decrease in MMS-induced
expression of three NF-kB target genes, IkBa, Cox2, and
TNFa, following knockdown of TSC2 expression as assayed
by real-time PCR analyses (Figure 2C). We also transiently217
A R T I C L EFigure 2. siRNA knockdown of TSC2 or Rheb expression in HEK293 cells attenuates NF-kB target gene transcription, while reconstitution of TSC2 in TSC22/2MEFs
restores NF-kB activation and increases resistance to DNA damage-induced cell death in an NF-kB-dependent manner
A: TSC2 (top panel) or actin (bottom panel) immunoblot showing knockdown of TSC2 in HEK293 cells transfected with Stealth RNAi (Invitrogen).
B: Anti-myc (top panel) and actin (bottom panel) immunoblot showing Rheb expression in HEK293 cells.
C and D: Real-time PCR analyses in TSC2 siRNA-transfected, control siRNA-transfected, or Rheb-transfected HEK293 cells following 2 hr MMS treatment (C) or
2 hr TNFa treatment (D).
E: pNF-kBLuc reporter plasmid assay in Rheb-transfected HEK293 cells treated with TNFa for 6 hr.
F: Expression of Flag-tagged TSC2 in whole-cell lysates of TSC22/2 [R] MEFs.
G: TSC22/2and TSC22/2 [R] MEFs were treated with MMS for 2 hr (lanes 2 and 4), TNFa for 20 min (lanes 7 and 10), or IL-1 for 30 min (lanes 6 and 9) as described in
Figure 1E, and nuclear lysates were analyzed for NF-kB activation by EMSA.
H: Wild-type, TSC22/2, and TSC22/2 [R] MEFs were treated with MMS for 2 hr, doxorubicin for 6 hr, or TNFa plus cycloheximide for 3 hr as described in Figure 1A.
Cell viability was assayed by crystal violet staining.
I: TSC22/2 MEFs were reconstituted with TSC2 alone (TSC22/2 [R]), or sequentially with TSC2 and IkBaM (TSC22/2 [R] + IkBaM) by infecting them with lentiviral
vectors bearing respective expression constructs. Cell viability was assayed after MMS treatment for 2 hr. Bars in graphs represent means6 standard deviations.overexpressed the TSC2 target Rheb in HEK293 cells (Fig-
ure 2B), which leads to increased RhebGTP and activation of
mTOR, thus phenocopying the loss of TSC2 (Garami et al.,
2003; Im et al., 2002; Inoki et al., 2003). Similar attenuation of
NF-kB target gene induction was observed (Figure 2C).218TNFa-induced expression of IkBa, as a representative NF-kB
target, was also seen to be attenuated in TSC2 siRNA-treated or
Rheb-expressing HEK293 cells (Figure 2D). Similarly, overex-
pression of Rheb repressed induction of an NF-kB:luciferase
reporter plasmid by TNFa in HEK293 (Figure 2E) or HeLa cellsCANCER CELL SEPTEMBER 2006
A R T I C L E(Figure S2A). Thus, the effects of TSC2 on NF-kB activation are
mediated by negative regulation of Rheb.
Attenuated induction of NF-kB target genes in response to
MMS or TNFa, including IkBa, COX2, TNFa, and IL-8, was also
observed by real-time PCR analyses using a panel of human tu-
mor-derived cells lines (U2OS, MDA-MB-468, MCF7, and
HCT116), following transient siRNA-mediated knockdown of
TSC2 expression (Figures S2B and S2C). Taken together, these
results obtained in MEFs and in several different human tumor
cell lines strongly suggest that the loss of TSC2 per se, irrespec-
tiveofgeneticbackgrounds, results indefectiveNF-kBactivation.
To demonstrate conclusively that the observed defect in cell
survival and NF-kB activation was a consequence of the lack
of the TSC2 gene and not a result of unrelated alterations in
the genome of TSC22/2 MEFs, we reintroduced a Flag-tagged
TSC2 gene into these cells using a lentiviral expression vector.
Lentiviral vector-mediated expression of TSC2 restored TSC2
protein to a wild-type level in a pool of TSC22/2 MEFs (Fig-
ure 2F). NF-kB EMSA from TSC22/2-reconstituted (TSC22/2
[R]) MEFs showed a restoration of NF-kB activation following
MMS, TNFa, or IL-1 treatment (Figure 2G). Reconstitution of
the TSC2 gene was also sufficient to impart protection against
MMS, doxorubicin, or TNFa treatment to extents nearly resem-
bling those observed with wild-type MEFs (Figure 2H).
To verify if NF-kB activation directly mediated the observed
cell survival, we used a nondegradable mutant of IkBa, IkBaM.
This mutant lacks the inducible N-terminal (Ser32 and Ser36)
and constitutive phosphorylation sites in the C-terminal PEST
domain (Tergaonkar et al., 2003) and therefore functions as
a dominant-negative inhibitor of NF-kB activation. Lentivirus-
mediated expression of IkBaM in wild-type MEFs significantly
reduced cell survival following treatment with MMS or doxorubi-
cin, in comparison to uninfected control cells (Figure S3). While
reconstitution of TSC2 alone (TSC22/2 [R]MEFs) imparted resis-
tance to MMS (percent of cell death = 30.736 2.66), expression
of IkBaM in TSC22/2 [R] MEFs reduced cell survival to the levels
observed for TSC22/2 MEFs (percent of cell death = 63.47 6
10.12; Figure 2I). Infectionwith the IkBaM lentivirus did not affect
TSC2 expression (Figure 2F). The heterogeneity of expression
in the TSC2-reconstituted pool contributed to some variability
in survival in different experiments. However, IkBMa clearly ab-
rogated the prosurvival effects of the reconstituted TSC2. Our
results indicate that TSC2-dependent prosurvival signals func-
tion, at least in part, by activating the NF-kB pathway.
ERK1/2 signaling mediates NF-kB activation and cell
survival in response to DNA damage, while Akt functions
in TNFa-dependent NF-kB activation
A number of protein kinases regulate NF-kB activation either by
activating IKK or by modifying p65 after its release from IkB
molecules (reviewed in Viatour et al., 2005). Immunoblotting
with phospho-IKKaSer180/IKKbSer181-specific antibodies in-
dicated that IKKa/b was activated following 30 min of MMS
treatment in wild-type MEFs. Phosphorylation of these sites in
the kinase domain correlates with increased IKK kinase activity
(Delhase et al., 1999). In contrast, MMS treatment of TSC22/2
MEFs did not elicit sustained IKKa/b activation (Figure 3A, upper
panel). Similarly, MMS treatment led to phosphorylation of IkBa
at Ser32 in wild-type MEFs, but not TSC22/2 MEFs (Figure 3A,
middle panel). Immunoblotting with phospho-p65 Ser536-
specific antibodies demonstrated that this IKK-dependentCANCER CELL SEPTEMBER 2006phosphorylation site was phosphorylated in both wild-type
MEFs and TSC22/2 MEFs following MMS treatment. While the
phosphorylation was robust and sustained in wild-type MEFs,
TSC22/2 MEFs failed to sustain the increase in Ser536 phos-
phorylation (Figure 3B).
Correspondingly, while IKKa/b phosphorylation was also in-
creased in wild-type cells following TNFa treatment, no increase
in phosphorylation was observed in TSC22/2MEFs (Figure 3F).
Additionally, the kinetics of Ser536 phosphorylation following
TNFa treatment differed between wild-type and TSC22/2
MEFs, with TSC22/2 MEFs showing lower basal levels and
a lack of sustained phosphorylation at this site, similar to that
observed with DNA damage (Figure 3G). These data suggest
that MMS and TNFa treatment fails to activate the IKK complex
and maintain p65 transactivation in TSC22/2MEFs, resulting in
the lack of NF-kB activation.
Since deficiency of TSC1 or TSC2 leads to defects in PI-3K/
Akt signaling, and Akt is a well-known regulator of NF-kB activa-
tion (Gustin et al., 2004; Madrid et al., 2000; Mayo et al., 2002;
Osawa et al., 2002; Ozes et al., 2001; Reddy et al., 2000; Size-
more et al., 1999, 2002), we investigated if Akt plays a role in
NF-kB activation following MMS-induced DNA damage. We
failed to detect any significant increase in Ser473 phosphoryla-
tion in Akt following the treatment of wild-type, TSC22/2, and
TSC22/2 [R] MEFs with MMS (Figure 3C). Consistent with this
observation, no increase in Akt kinase activity was detected
by in vitro kinase assays following MMS treatment in wild-type
cells (data not shown). Furthermore, treatment with an Akt inhib-
itor, A-443654 (1 mM) (Luo et al., 2005), did not enhance MMS-
stimulated cell death in either wild-type or TSC22/2 MEFs, nor
did it affect MMS-induced NF-kB-dependent gene expression
in wild-type MEFs (data not shown). Therefore, Akt does not
appear to be a major regulator of DNA damage-induced
NF-kB activation in these cells.
Activation of NF-kB by TNFa requires activation of PI-3K and
its downstream target, Akt (Ozes et al., 1999). In our studies,
stimulation of wild-type MEFs with TNFa (10 ng/ml) resulted in
an increase in Akt activation within 10 min of TNFa stimulation,
with maximal activation at 30 min (Figure 3H). Additionally, A-
443654 blocked TNFa-inducedNF-kB-dependent gene expres-
sion (Figure S4D). Consistent with reports that the PI-3K inhibi-
tors LY294002 and wortmannin block TNFa-induced NF-kB
activation in many cell types (Gustin et al., 2004), LY294002
prevented TNFa-induced NF-kB activation in wild-type MEFs
(Figure S4E). In contrast, TSC22/2 MEFs, which had a lower
basal level of Akt Ser473 phosphorylation, did not show any in-
duction following TNFa treatment (Figure 3H). Furthermore, both
the activating phosphorylations, Thr308 and Ser473, on Akt
were restored in a TNFa-dependent manner following reconsti-
tution of TSC2 (Figure 3I). It is interesting to note that TNFa treat-
ment of wild-typeMEFs induced phosphorylation of TSC2 at the
Akt phosphorylation site Thr1462, suggesting that downregula-
tion of TSC2 may be required for feedback regulation of TNFa
signaling and NF-kB downregulation (Figure 3J). We conclude
that Akt activation in response to TNFa is defective in TSC22/2
MEFs and that this difference could well account for defective
NF-kB-dependent gene expression and protection against
TNFa-induced cell death in these cells.
A number of protein kinases have been implicated in regulat-
ing NF-kB activity (Viatour et al., 2005). We investigated the
activation of candidate kinases following MMS treatment in219
A R T I C L EFigure 3. ERK1/2 activation in response to DNA damage is suppressed in TSC2-deficient MEFs
Wild-type and TSC22/2 MEFs were treated with MMS as indicated (A, B, and D) or for 2 hr (C and E), and whole-cell lysates were analyzed by immunoblotting
with phospho-IKKa/b Ser180/181, phospho-IkBa Ser32, and actin antibodies (A); phospho-p65 Ser536 and p65 antibodies (B); phospho-Akt, Akt, phospho-p38
Thr180/Tyr182, and p38 antibodies (C); or phospho-ERK1/2 Thr202/185/Tyr204/187 and ERK1/2 antibodies (D and E) at the indicated time points. TSC22/2 [R]
MEFs were included in some experiments (C and E). Alternatively, wild-type and TSC22/2 MEFs were treated with TNFa as indicated (F–H) or for 20 min
(I and J), and cells were lysed at various time points as indicated. Akt (I) or TSC2 (J) was immunoprecipitated, or whole-cell lysates (F–H) were subjected to
immunoblotting with phospho-IKKa/b Ser180/181 and IKKa (F); phospho-p65 Ser536 and p65 (G); phospho-Akt Ser473 and Akt (H); phospho-Akt Thr308,
phospho-Akt Ser473, and Akt (I); or phospho-TSC2 Thr1462 and TSC2 (J) antibodies.wild-type and TSC22/2MEFs. While some kinases, such as Akt
and GSK3 (data not shown), did not show any activation
following DNA damage, p38 MAP kinase was activated, but to
a similar extent in bothwild-type and TSC22/2MEFs (Figure 3C).
Additionally, the p38 MAP kinase inhibitor SB203580 (10 mM)
treatment caused no increase in MMS-induced cell death in
TSC22/2 MEFs (data not shown). These results indicate that,
although p38 MAP kinase may play a role in DNA damage-
dependent NF-kB activation, this result cannot account for the
differences in cell survival observed between wild-type and220TSC22/2 MEFs. Investigation of the activation-specific phos-
phorylation of ERK1/2 indicated that ERK1/2 was induced
between 15 and 30 min following MMS exposure and showed
sustained activation in wild-type MEFs up to 2 hr (Figure 3D).
In contrast, TSC22/2 MEFs failed to show sustained activation
of ERK1/2 in response to MMS. Reexpression of TSC2 in
TSC22/2 [R] MEFs partially restored sustained ERK1/2 activa-
tion following treatment with MMS (Figure 3E). Additionally,
theMEK1/2 inhibitor U0126, which blocks ERK1/2 activation, in-
hibited MMS-induced IKKa/b phosphorylation, inhibited NF-kBCANCER CELL SEPTEMBER 2006
A R T I C L Eactivation, and reduced cell survival in wild-type MEFs (Figures
S4A, S4B, and S4C). Taken together, our results show a correla-
tion between the difference in ERK1/2 activity in wild-type and
TSC22/2 MEFs and the differences in NF-kB activation and
DNA damage sensitivity in these two cell lines. We did not
observe any induction of ERK1/2 activation following TNFa stim-
ulation in either cell type. These results indicate that the TSC1-
TSC2 complex modulates NF-kB activation under a variety of
different conditions by regulating IKKa/b activation. It is interest-
ing to note that the molecular mechanisms for activation of NF-
kB following DNA damage versus TNFa stimulation, although
both showing a requirement for TSC2, involve different signal
transduction pathways: DNA damage activates the ERK1/2
MAP kinase pathway, whereas TNFa signaling involves Akt.
Previous results from this laboratory have shown that rapamy-
cin treatment protects TSC22/2 cells from camptothecin- or
etoposide-induced cell death (Shah et al., 2004). Therefore,
we tested if cell death induced by other classes of DNA-damag-
ing agents, such as MMS, is also blocked by rapamycin treat-
ment. TSC12/2 or TSC22/2 MEFs were pretreated overnight
with 200 nM rapamycin and then subjected to MMS treatment.
Rapamycin pretreatment significantly protected both TSC12/2
and TSC22/2 MEFs from MMS-induced cell death (Figure 4A).
Quantitative analyses demonstrated that rapamycin pretreat-
ment reduced MMS-induced cell death in TSC22/2 MEFs to
3.62% 6 5.12% (Figure 4B).
To investigate the mechanism of rapamycin-induced protec-
tion, we blocked the activation of different signaling compo-
nents upstream of NF-kB using specific inhibitors and assessed
the effect on rapamycin-induced survival of MMS-treated
TSC22/2 cells.Wild-typeMEFs or TSC22/2MEFs that were pre-
treated overnight with rapamycin were treated with U0126,
LY294002, or SB203580. Following treatment with the U0126
(50 mM) or LY294002 (20 mM), but not SB203580 (10 mM), rapa-
mycin-treated TSC22/2 MEFs showed dramatically increased
sensitivity to MMS-induced DNA damage (percent of cell death
with U0126 = 55.87 6 9.92 and percent of cell death with
LY294002 = 51.16 6 16.50) (Figure 4C). Consonantly, ERK1/2
activation was partially restored in TSC22/2 cells in the pres-
ence of rapamycin (Figure 4D), and rapamycin treatment re-
stored NF-kB activation (Figure 4E). Similarly, rapamycin treat-
ment restored Akt activation following TNFa treatment in
TSC22/2 MEFs (Figure 4G), and this correlated with increased
NF-kB activation (Figure 4H). The rapamycin-dependent rescue
of NF-kB activation following MMS or TNFa treatment was in-
hibited by U0126 or LY294002, respectively (Figures 4F and 4I).
We also tested the effects of directly interfering with NF-kB
activation following rapamycin pretreatment on cell survival,
by using a cell-permeant quinazoline compound that acts as
a potent inhibitor of NF-kB transcriptional activation (Correa
et al., 2005; Tobe et al., 2003). 6-Amino-4-(4-phenoxyphenyle-
thylamino) quinazoline (NAI) (20 mM) treatment, which specifi-
cally blocked NF-kB-dependent transcription (Figure S5), effec-
tively reversed the rapamycin-mediated protection from
MMS-induced cell death (Figure 4C). Thus, in the absence of
TSC2, an mTOR-dependent feedback mechanism results in
ERK1/2, Akt, and NF-kB downregulation. Rapamycin treatment
rescues ERK1/2 and Akt activation, and consequently NF-kB
activation. Inhibition of NF-kB activation or upstream signaling
overcomes rapamycin-induced chemoresistance in TSC22/2
MEFs.CANCER CELL SEPTEMBER 2006The molecular mechanisms of TSC2-dependent ERK1/2 and
Akt activation remainunclear. Thismayoccur throughacommon
or distinct pathway and awaits further investigation. Akt is
a target of negative regulation in the absence of TSC2 through
an mTOR-S6K1-regulated feedback pathway that inactivates
IRS-1 by multiple means, including phosphorylation, protein
degradation, and transcriptional downregulation (Harrington
et al., 2005; Shah andHunter, 2005). The absence of TNFa-stim-
ulated Akt activation and its restoration upon rapamycin treat-
ment is consistent with such an mTOR-mediated downregula-
tion of PI-3K and Akt in TSC22/2 MEFs. In some, but not all
cell types, inhibition of PI-3K leads to suppression of ERK1/2
activity (Chaudhary et al., 2000; Cross et al., 1994; Duckworth
and Cantley, 1997; King et al., 1997). Thus, it is conceivable
that mTOR-mediated negative regulation of PI-3K in TSC22/2
MEFs may also modulate ERK1/2 activation. TSC2 expression
increased ERK1/2 phosphorylation and B-Raf kinase activity in
TSC22/2 ELT3 cells, whereas siRNA downregulation of TSC2
resulted in decreased ERK1/2 phosphorylation in HEK293 cells
(Karbowniczek et al., 2004). Conversely, Rheb expression de-
creased ERK1/2 phosphorylation, further supporting a role for
TSC2 in ERK1/2 regulation. However, this regulation appears
to be mTOR independent. Interestingly, Finlay et al. (2005)
have reported a similar temporal pattern of PDGF-dependent
ERK1/2 phosphorylation, yet reduced nuclear translocation of
ERK1/2 in TSC22/2, in comparison to TSC2-reconstituted
ELT3 cells. The mechanism of ERK activation in TSC22/2 cells,
in contrast to TSC2+/+ cells, was independent of MEK but de-
pendent on reactive oxygen and mTOR. During our studies,
we noted that transient activation of ERK1/2 following EGF or
TPA stimulation was comparable between wild-type and
TSC22/2MEFs, suggesting that the defect in ERK1/2 activation
may be signal specific and limited to sustained activation
(Figure S6). However, other investigators did not observe any ef-
fect of the TSC1-TSC2 complex on ERK1/2 (Garami et al., 2003;
Tee et al., 2003). On the basis of the time course required for ra-
pamycin-mediated rescue of Akt or ERK1/2 activation, we can-
not rule out complex feedback regulation that may require tran-
scription/translational rather than a direct phosphorylation of
substrates by mTOR. Nevertheless, our results establish that
there is a crosstalk between the TSC/Rheb/mTOR and the NF-
kB pathways that modulates cell survival.
In conclusion, our results demonstrate that the TSC1-TSC2
complex is an important modulator of NF-kB activation. In our
model (Figure 5), DNA damage causes activation of ERK1/2
through a pathway whose details remain to be fully elucidated,
and this in turn results in activation of IKK and NF-kB. Stimula-
tion of the TNFa receptor elicits Akt activation, and this leads
to similar activation of IKK and NF-kB. The molecular details
of IKK activation following activation of ERK1/2 or Akt remain
unexplored. Nonetheless, with both stimuli, high mTOR activity,
as found in TSC22/2 cells, blocks coupling to IKK at the level
of ERK1/2 and Akt, respectively. Based on the effects of
small molecule inhibitors on cell survival, we deduce that resis-
tance of rapamycin-treated TSC22/2 cells to DNA damage-
induced cell death requires PI3-K activity, ERK activation, and
most importantly, downstream NF-kB activation. While other
pathways, such as HIF1a or Akt/PKB and ERK-dependent,
NF-kB-independent cell survival pathways, such as FOXO
or Bim phosphorylation (O.J. Shah and T.H., unpublished
data), may also be important, our results demonstrate that221
A R T I C L EFigure 4. Treatment with rapamycin protects against increased DNA damage-sensitive cell death and rescues ERK1/2 signaling and NF-kB activation in
TSC22/2 MEFs
Aand B: TSC12/2or TSC22/2MEFs were pretreated overnight with 200 nM rapamycin (Rap) or left untreated. Subsequently, MEFs were exposed to MMS for 2 hr,
and cell viability was analyzed. Crystal violet staining (A) or bar graph representing survival determined by trypan blue staining (B) are shown. Bars in graphs
represent means 6 standard deviations.
C:Cell viability in TSC22/2MEFs treated with MMS for 2 hr in combination with U0126 (50 mM), NF-kB inhibitor (NAI) (20 mM), LY294002 (20 mM), or SB203580 (10 mM)
following overnight treatment with 200 nM rapamycin. Cells were pretreated for 30 min with inhibitors alone prior to the application of MMS. Bars in graphs
represent means 6 standard deviations.
D and E: TSC22/2 MEFs or TSC22/2 MEFs pretreated overnight with 200 nM rapamycin were treated with MMS, and whole-cell lysates were analyzed by immu-
noblotting with phospho ERK1/2 or ERK1/2 antibodies at various times as indicated (D), or NF-kB DNA binding activity in nuclear lysates was analyzed by EMSA (E).
F: TSC22/2MEFs pretreated overnight with 200 nM rapamycin or TSC22/2MEFs pretreated overnight with 200 nM rapamycin and subsequently with U0126 for 30
min were further treated with MMS or MMS in combination with U0126 for 2 hr, respectively. NF-kB DNA binding activity in nuclear lysates was analyzed by EMSA.
G and H: TSC22/2 MEFs were left untreated or pretreated overnight with 200 nM rapamycin and subsequently treated with TNFa for 20 min. Lysates were
analyzed by immunoblotting with phospho-Akt Ser473 or Akt antibodies (G), or NF-kB DNA binding activity in the nuclear lysates was analyzed by EMSA (H).
I: TSC22/2MEFs pretreated overnight with 200 nM rapamycin or TSC22/2MEFs pretreated overnight with 200 nM rapamycin and subsequently with LY294002 for
30 min were further treated with TNFa or TNFa in combination with LY294002 for 20 min, respectively. NF-kB DNA binding activity in the nuclear lysates was
analyzed by EMSA.NF-kB signaling is a critical component in TSC2-mediated cell
survival.
Deregulation of the NF-kB pathway is associated with onco-
genesis, malignancies, and metastasis (Baldwin, 2001; Huber
et al., 2004; Karin et al., 2002). The lack of activation of the NF-
kB-dependent cell survival pathway inTSC22/2cellsmaypoten-
tially explain the relatively weak malignancy in TSC-derived
tumors. NF-kB activation also contributes to the antiapoptotic
function of insulin and may contribute to insulin-mediated
survival in these cells (Bertrand et al., 1998). Additionally, we
demonstrate that NF-kB activation is a critical mechanism that
contributes to chemoresistance and cell survival in rapamycin-222treated TSC22/2 MEFs. Several recent reports have demon-
strated that combined therapeutic approaches are required for
the treatment of tumors with mutations in the Akt signaling path-
way because of redundant proliferation pathways (O’Reilly et al.,
2006; Raje et al., 2004; Xing and Orsulic, 2005). The NF-kB
pathway is an attractive target for overcoming antiapoptotic
responses to promote chemosensitivity in various cancers
(Cusack, 2003). Our studies indicate a need for combinatorial
targeting of mTOR plus the NF-kB pathway to maximize the
benefits of anticancer therapeutics for TSC-derived tumors.
Although strongly suggestive, it remains to be documented
if activation of the NF-kB pathway by rapamycin in humanCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 5. Model depicting NFkB activation and cell survival/chemoresistance in wild-type, TSC22/2, and TSC22/2 MEFs treated with rapamycin following
treatment with TNFa and MMS/doxorubicin
The three panels represent pathways leading to NF-kB activation downstream of TNFa and MMS/doxorubicin-induced DNA damage in wild-type, TSC22/2,
and TSC22/2MEFs treated with rapamycin. Increased mTOR activity in TSC22/2MEFs (middle panel) results in the downregulation of signaling to Akt and ERK1/
2 (red bars), as depicted by the lighter shade of the downstream NF-kB pathway components. This is reversed upon rapamycin-induced inhibition of mTOR.TSC-derived tumors plays a role in the acquisition of chemore-
sistance. Further studies are required to determine if targeting
NF-kB activation and its upstream signaling components,
together with rapamycin therapy, may enhance the efficacy of
therapeutic regimens in tuberous sclerosis patients.
Experimental procedures
Cell culture and reagents
TSC2+/+ p532/2 and TSC22/2 p532/2 (Kwiatkowski et al., 2002) or TSC1+/+
p53+/+ and TSC12/2 p53+/+ MEFs (Zhang et al., 2003), as well as U2OS,
MDA-MB-468, MCF7, and HCT116 cells were cultured in DMEM supple-
mented with 10% FCS (Hyclone), 100 mg/ml penicillin, 100 mg/ml streptomy-
cin, and 250 ng/ml amphotericin B (Gibco). Doxorubicin,MMS, and LPSwere
purchased from Sigma. TNFa, IL-1, U0126, NF-kB activation inhibitor (NAI)
(cat. no. 481406), LY294002, SB203580, and rapamycin were obtained
from Calbiochem.
Antibodies
IKKa, p65 (RelA), IkBa, and TSC2 (tuberin) antibodies were obtained
from Santa Cruz Biotechnology. Phospho-IKKa/b Ser180/Ser181, Akt,
phospho-Akt Thr308, phospho-Akt Ser 473, phospho-p65 Ser536,
ERK1/2, phospho-TSC2 Thr1462, phospho-IkBa Ser 32, gH2AX, and acti-
vated caspase 3 Asp175 antibodies were obtained from Cell Signaling
Technology. Phospho-ERK1/2 Thr183/Tyr185, Flag-M2 antibodies, and
b-actin antibodies were purchased from Sigma. p38a was obtained from
R&D Systems. Phospho-p38 Thr180/Tyr182 antibodies were from Zymed.
Phospho-ATM Ser1981 antibodies were from Rockland Immunochemicals,
Inc.
Cell survival assay and statistical analyses
MEFs were treated with 0.01% MMS or 0.7 mg/ml doxorubicin or 10 ng/ml
TNFa as described or with vehicle alone (DMSO/cycloheximide 5 mg/ml)
for the indicated time. Culture dishes were washed three times withCANCER CELL SEPTEMBER 2006phosphate-buffered saline (PBS), and remaining adherent cells were fixed
and stained with 0.05% crystal violet solution in 20% ethanol. Alternatively,
cell viability was assessed by trypan blue staining. Three representative sam-
ples from a uniform suspension of MEFs were diluted 1:10 in 0.4% trypan
blue (Sigma). The number of viable cells was determined by counting the try-
pan blue-excluding cells in a hemocytometer. The percent of cell viability was
calculated from the ratio of the number of viable cells (trypan blue-excluding
or nonapoptotic cells) divided by the total number of cells. The mean6 stan-
dard deviation was calculated from three independent experiments.
EMSA
Nuclear extracts were prepared, and EMSA were performed as described
previously (Tergaonkar et al., 2002).
Immunofluorescence analysis
Cells grown on coverslips were washed with cold PBS and fixed for 30 min in
4% paraformaldehyde at room temperature. Fixed cells were permeabilized
with PBS-1% Triton X-100, blocked with 10% normal goat/horse serum, and
incubated with the antibodies mentioned in the text. After extensive washes,
the primary antibodies were visualized with Rhodamine red-X (Jackson
ImmunoResearch Labs)-labeled fluorescent secondary anti-rabbit Ig anti-
bodies using a Zeiss scanning confocal microscope.
RNA extraction and reverse transcription
After stimulation, cells were harvested, and total RNA was isolated using the
RNeasy mini kit (Qiagen). Reverse transcription was performed according to
the manufacturer’s instructions with RT Superscript III (Invitrogen Life Tech-
nologies).
Real-time PCR analysis
PCR reactions were performed on a ABI Prism 7700 Sequence Detection
System using SYBRGreen PCR master mix (Applied Biosystems, Warring-
ton, UK). Real-time PCR analyses are represented as a ratio of the gene-spe-
cific transcripts over 18S rRNA, normalized to untreated wild-type.223
A R T I C L ETSC2 knockdown and expression of Rheb
Various cell lineswere transfectedwith pooled validated TSC2Stealth RNAi 1
and 2 or pooled Stealth RNAi Negative Control LO GC and Stealth RNAi
Negative Control Med GC (Invitrogen) at a final concentration of 50 nM using
Lipofectamine 2000 according to the manufacturer’s suggested protocol.
Myc-tagged Rheb in pRK7 (Tee et al., 2003) was transfected using Effectene
(Qiagen) or by calcium phosphate method. Cells were assayed 48–72 hr
posttransfection.
NF-kB luciferase reporter assays
HEK293 cells (23 105) were plated into six-well plates and, after overnight in-
cubation, cotransfected with 0.5 mg of pNF-kBLuc reporter plasmid in com-
bination with 0.2 mg of pCMV-LacZ plasmid and Rheb-expressing plasmid
using calcium phosphate. Corresponding empty vector was included in
some transfections as control. Two milligrams of total DNA amount was
used per transfection. Forty-eight hours posttransfection, cells were treated
for 8 hr with TNFa, lysates were prepared, and luciferase activity and b-galac-
tosidase activity were measured. Luminometric and colorimetric reactions
were read on the Wallac 1420 plate reader (Perkin Elmer). Luciferase activity
was corrected for transfection efficiency using b-galactosidase activity of
cotransfected pCMV-LacZ plasmid. Fold reduction after Rheb transfection
was normalized to TNFa-induced maximum luciferase activity with control
transfection.
Immunoblots and immunoprecipitations
MEFs were washed with PBS and harvested in RIPA buffer. Whole-cell ly-
sates were resolved by electrophoresis, and proteins were transferred onto
PVDF membrane (Immobilon P, Millipore), blocked in TBS containing 0.2%
Tween-20 (TBST) and 3% BSA and probed with the indicated antibodies in
TBST with 3% BSA.
For immunoprecipitations, total cell lysates were prepared in a buffer con-
taining 50mMTris$HCl (pH 8), 170mMNaCl, 0.5%Nonidet P-40, 50mMNaF
supplemented with complete protease inhibitors (Roche), and phosphatase
inhibitors I and II (Sigma) at 4C. Immunoprecipitations were performed after
preclearing the lysates for 1 hr by incubation with protein A-Sepharose
(Amersham Biosciences). Precleared supernatants were incubated over-
night with primary antibodies at 4C, and protein A-Sepharose beads were
added for the last 2 hr. The immunoprecipitates were washed three times
with 10 mM Tris$HCl (pH 8), 250 mM NaCl, 5 mM EDTA, 0.5% Nonidet
P-40, and complete protease inhibitors.
Generation of lentiviral vectors and cell lines
The LV-GFP and LV-TSC2 constructs were derived from p156RRLsin-
PPTPGK-eGFP-PRE vector, wherein the transgene is driven by the CMV
promoter. The production of lentiviruses was performed as per standard
protocols (Ikawa et al., 2002). To generate cell lines, TSC22/2MEFs were in-
fected with either pLV-GFP or pLV-TSC2 lentiviral vectors. Pools of infected
cells were used in the assays described.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
six figures and can be found with this article online at http://www.cancercell.
org/cgi/content/full/10/3/215/DC1/.
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